TDC
CRSP icon

Thompson Davis & Co’s CRISPR Therapeutics CRSP Stock Holding History

Thompson Davis & Co’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$6K Hold
125
– – 0.01% 535
2018
Q2 		$7K Sell
125
-325
-72% -$18.5K 0.02% 472
2018
Q1 		$21K Buy
450
+325
+260% +$13.4K 0.06% 283
2017
Q4 		$3K Buy
+125
New +$2.38K 0.01% 569
2017
Q2 		– Sell
-2,500
Closed -$54K – 1096
2017
Q1 		$54K Buy
+2,500
New +$49.1K 0.08% 240

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Thompson Davis & Co's CRSP Position: Q3 2018 in Review

Thompson Davis & Co held its CRISPR Therapeutics (CRSP) position steady in Q3 2018 at 125 shares worth $6K. The position accounts for 0.01% of the portfolio, ranked #535.

Thompson Davis & Co first reported a position in CRSP in Q1 2017 and has held it in 5 quarters since. The position peaked at $54K in Q1 2017. 179 funds tracked by Wall St. Rank hold CRSP as of Q3 2018.

  • Thompson Davis & Co held 125 shares of CRISPR Therapeutics worth $6K as of Q3 2018.
  • Thompson Davis & Co left its CRISPR Therapeutics share count unchanged in Q3 2018.
  • CRISPR Therapeutics made up 0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #535 holding.
  • Thompson Davis & Co first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 5 quarters since.
  • Thompson Davis & Co's CRISPR Therapeutics position peaked at $54K in Q1 2017.
  • 179 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.